DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington's Disease Drug Development

Friday, November 22, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington's disease (HD).

ST. PETERSBURG, Fla., Nov. 21, 2019 /PRNewswire-PRWeb/ -- MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington's disease (HD). "As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions," said Elio Mariani, PhD, EVP of Research & Development. "Patients will benefit from cGMP-quality therapies in an accessible and efficient format."

Most recently the FDA awarded MMJ International Holdings ?Orphan Drug Designation? for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington's Disease. MMJ is confident that their pharmaceutical drugs will bring much needed relief to patients suffering from the debilitating effects of Multiple Sclerosis and Huntington's Disease. "We firmly believe that our MMJ natural whole plant derived molecules with a unique combination of pharmacological properties will be FDA approved as a safe and effective prescription drug that can be of great benefit in treating patients with MS and HD diseases," said Duane Boise, CEO of MMJ International Holdings."We are pleased with the DEA 's cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases." Tim Moynahan the company chairman stated that "Patients in the MMJ International holdings clinical trials will receiv e gelatin capsules containing THC and CBD daily."

MMJ International Holdings has several academic institutions preparing to study cannabis in Multiple Sclerosis and Huntington's disease. "MMJ clinical trials will provide the necessary data to prove that cannabis can treat essential tremors, a neurological disorder that causes involuntary shaking." Tim Moynahan further stated that, "Ultimately, there's so much interest in THC and CBD as a treatment modality, so MMJ will be providing the clinical research data necessary to prove patient dosing, safety, and efficacy." MMJ International Holdings continues its process of scientific drug development and discovery by FDA protocol development processes, intellectual property portfolio and DEA regulatory manufacturing guidelines.

About MMJ International Holdings:

MMJ International Holdings has established a leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise. MMJ is successfully developing several prescription medications derived from the cannabis plant for the treatment of spasticity and chorea due to multiple sclerosis and Huntington's disease.

The company has a pipeline of additional clinical stage cannabinoid and other natural botanical product candidates for both orphan and non-orphan indications with a specific focus on neurological conditions.

For more information visit: http://www.mmjih.com

For media inquiries please contact:

Michael Sharp 561-627-9455

For Investment Opportunities:

MFS Capital Advisors 917-562-9610

SOURCE: MMJ International Holdings

 

SOURCE MMJ International Holdings



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store